Cambridge Research Biochemicals (CRB), a leading independent producer of custom-made peptide and antibody tools,  and Key Organics Limited (Key Organics),  a Tennant Group of Companies and a leading supplier of R&D compounds and chemistry contract research services to the international life sciences industries,  have entered into a worldwide exclusive supply & marketing agreement that makes CRB’s peptides available to Key Organics’ global life science customer base through its online BIONET catalogue.

Emily Humphrys, commercial director at CRB commented: “Our partnership with Key Organics will allow us to expand the reach of our growing peptide product portfolio to a global market. We will continue to focus on our core peptide activities, serving our key customers with bespoke custom-made peptides, whilst Key Organics sells our new catalogue peptide range.”

Joe Carey, managing director at Key Organics added: “We have been seeking to extend our product range in the peptide area so are delighted to enter into this agreement with CRB. The Company has established itself as a world leader in peptide chemistry with an excellent quality and service record that conforms to the standards we have established for our BIONET portfolio."

Since CRB was established in 1980, the company quickly became a global leader in the supply of custom–made peptides and has recently expanded its premises in Billingham, UK. CRB continues to develop the range of products and services offered and can supply all flavours of peptides. This encompasses simple to heavily modified targets and various labels can be incorporated, including stable-isotopes, radio-isotopes and fluorescent dyes.  Milligram to gram-scale quantities are offered, at the highest levels of purity.

Within its BIONET brand, Key Organics offers an extensive range of over 74,000 screening compounds, intermediates, building blocks and biochemicals to the international pharmaceutical, biotechnology and agrochemical industries. With new premises near Boston, USA, Key Organics is able to supply its BIONET products to the North American market.